08:01 AM EDT, 10/20/2025 (MT Newswires) -- CorMedix ( CRMD ) reported Q3 preliminary net revenue Monday of $100 million, including at least $85 million for DefenCath.

Analysts polled by FactSet expected sales of $66.4 million and DefenCath sales of $57.2 million.

The company reported preliminary pro forma Q3 net revenue of more than $125 million.

CorMedix ( CRMD ) raised its full-year 2025 pro forma net revenue outlook to at least $375 million from the prior range of $325 million to $350 million. Analysts surveyed by FactSet expect sales of $248.7 million.

As of Sept. 30, CorMedix ( CRMD ) said it had $56 million in cash, cash equivalents, and short-term investments on hand. The company expects year-end cash and cash equivalent balance of around $100 million.

CorMedix ( CRMD ) shares were up more 12% in recent Monday pre-bell activity.